TX-33
Prevention of scar tissue formation (arthrofibrosis) after joint injury or surgery
Key Facts
About Temple OrthoBiologics
Temple OrthoBiologics is a private, preclinical-stage biotech focused on the significant unmet need of preventing arthrofibrosis, a common and debilitating complication of joint trauma and orthopedic surgery. The company's core asset is TX-33, a potential first-in-class intra-articular drug candidate aimed at modulating the biological pathways that lead to excessive scar tissue and joint stiffness. With a founding team combining elite surgical, scientific, and athletic expertise, the company is positioning itself at the intersection of sports medicine and regenerative orthopedics. Its success hinges on translating its scientific approach into clinical proof-of-concept and navigating the competitive orthobiologics landscape.
View full company profile